ClinicalTrials.gg
RecruitingNCT07282587Updated Oct 29, 2026

Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma

A Phase 2 interventional study of ONC206 and ONC206: Dose 1 in Advanced Pheochromocytoma and Paraganglioma and PCPG, sponsored by Jazz Pharmaceuticals. Recruiting at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Jazz Pharmaceuticals · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Oct 29, 2026Site recruiting status changed1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies in Paraganglioma with a site in United States — 17 open to participants now, 23 under way, none of them phase 3. Paraganglioma · United States.

Planned enrollment
12th of 42
90 · median 34
Started
2026
with 1 other
Phase 2
24 of 49
6 open now
Primary completion
2028-12
later than 11 of 22 live
Registered
46th of 49
by date

Among the 49 studies in Paraganglioma with a site in United States, this one is the 12th largest by planned enrollment of the 42 interventional ones that give a count, is one of 2 that started in 2026, is one of 24 in phase 2, reaches primary completion later than 11 of the 22 other live ones, and was the 46th registered.

Paraganglioma

107 studies on the registry are indexed under Paraganglioma; 48 are open to participants now.

Browse Paraganglioma studies →

Open to participants now

17 of the 49 studies in Paraganglioma with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 36 Paraganglioma studies recruiting now, 21 (58%) set no upper age limit and 3 (8%) stop at 75 or younger; 12 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Paraganglioma with a site in United States, or all of them as a file.
02

Study summary

This is a two-stage Phase 2 trial evaluating the efficacy and safety of ONC206 in participants with Pheochromocytoma and Paraganglioma (PCPG).

Read the detailed description

Two-Stage Study to evaluate ONC206 as monotherapy doses:

Stage 1: Participants will receive 150mg ONC206 twice daily, on three consecutive days per week (BID TIW) in each 28-day cycle.

  • Part A: Initial number of participants will be monitored.
  • Part B: If a set number of participants have a response, then more participants will be enrolled and treated.

Stage 2: If Stage 1 meets the planned response, the study will proceed, and participants will be randomized 1:1 to receive 1 of 2 ONC206 dose levels.

03

Conditions studied

  • Advanced Pheochromocytoma and Paraganglioma
  • PCPG

Browse trials for

Keywords

  • PCPG
  • ONC206
  • JZP3507
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has confirmed pheochromocytoma or paraganglioma that is unresectable as determined by the Investigator.
  2. Has failed, is not a candidate for, or has declined standard of care treatment for PCPG. There is no limit on the number of prior systemic therapies.
  3. Must have per v1.1, as assessed by the Investigator.
  4. Has adequately controlled blood pressure defined as blood pressure ≤150/90 mmHg and with no change in antihypertensive medications (for participants with concomitant hypertension) for at least 14 days before the first dose of study treatment.
  5. Is ≥18 years of age.
  6. Is able to swallow oral tablets.
  7. Has an (ECOG) Performance Status of 0 to 2, assessed within 7 days before the first dose of study treatment.
  8. Has laboratory test results meeting the following parameters within 14 days before the first dose of study treatment
  9. Has an expected survival of at least 12 weeks, as predicted by the physician.
  10. Has pharmacologic control of catecholamine-associated symptoms if participant has functional disease.

Exclusion criteria

Exclusion criteria:

  1. Has known to ONC206 or any used in the ONC206 study treatment formulation.
  2. Has active cardiac disease/condition including any of the following:

    1. interval (QTc) >480 msec (based on the mean from triplicate [ECGs] performed during Screening).
    2. History of documented congestive heart failure ( function classification III-IV).
    3. Unstable angina, acute myocardial infarction, or arterial bypass or percutaneous transluminal coronary angioplasty within 6 months before the first dose of study treatment.
  3. Has previous exposure to ONC206 or dordaviprone (ONC201) from any source.
  4. Has a known additional that is progressing or has required active treatment within the past 2 years. Exceptions include participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer, or Von Hippel-Lindau disease-associated tumors that do not require immediate surgery or intervention.
  5. Has received any of the following interventions within the specified time periods before the first dose of study treatment or plans to receive any of the following interventions during study participation:

    • a. Any prior anticancer therapy or agents within 4 weeks or 5 half-lives, whichever is shorter. Note: Denosumab and zoledronic acid are permissible.

      **i. Any treatment with somatostatin analog or lanreotide within 21 days before the baseline Positron Emission Tomography (PET) scan.

    • b. Strong cytochrome P450 (CYP) inhibitors within 14 days. c. Strong CYP inducers within 14 days. d. Any radiotherapy within 14 days. e. Any major surgery, open or significant traumatic injury within 1 month (30 days).
  6. Is pregnant, breastfeeding, or planning to become pregnant while receiving study treatment or within 3 months after the last dose.
  7. Has uncontrolled intercurrent illness or any other medical, psychiatric, or social condition that, in the opinion of the Investigator, may interfere with participant safety or the ability to comply with study requirements.
  8. Has unresolved toxicities from previous locoregional, systemic, or any other therapies, defined as toxicities (other than Grade ≤2 neuropathy or alopecia) not yet resolved to the National Cancer Institute Grade ≤1, or baseline and considered ; consult with Medical Monitor.
  9. Has an active infection that requires systemic therapy.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Stage 1 Participants

    150 mg ONC206 BID TIW

    Drug: ONC206

  • Experimental
    Stage 2: Dose 1

    Participants receiving ONC206 at dose (To be Determined \[TBD\] post stage 1).

    Drug: ONC206: Dose 1

  • Experimental
    Stage 2: Dose 2

    Participants receiving ONC206 at dose (TBD post stage 1).

    Drug: ONC206: Dose 2

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    ORR defined as the number of participants with a confirmed complete response (CR) or partial response during the study, as per RECIST v1.1.

    Time frame: Up to 36 months.

Secondary outcomes

  1. Duration of Response (DOR)

    Time frame: Up to 36 months.

  2. Time to Response (TTR)

    Time frame: Up to 36 months.

  3. Disease Control Rate (DCR)

    Time frame: Up to 36 months.

  4. Progression Free Survival (PFS) by RECIST v1.1

    Time frame: Up to 36 months.

  5. Overall Survival (OS)

    Time frame: Up to 36 months.

  6. Change from Baseline in Antihypertensive Medication Dose

    Time frame: Up to 36 months.

  7. Change from Baseline in Biochemical Response (Metanephrines/Disease Markers)

    Time frame: Up to 36 months.

  8. Incidence of Adverse Events (AEs)

    Time frame: Up to 36 months.

  9. Number of Participants with Clinically Significant Changes from Baseline in Clinical Laboratory Parameters

    Time frame: Up to 36 months.

  10. Number of Participants with Grade 4+ Clinical Laboratory Parameters

    Time frame: Up to 36 months.

  11. Number of Participants with Clinically Significant Changes from Baseline in Electrocardiogram (ECG) Parameters

    Time frame: Up to 36 months.

  12. Maximum Observed Concentration of ONC206

    Time frame: Up to 36 months.

  13. Time of Maximum Observed Concentration (Tmax) of ONC206

    Time frame: Up to 36 months.

  14. Area Under the Concentration-Time Curve Extrapolated to Infinity (AUCinf)

    Time frame: Up to 36 months.

  15. Area Under the Concentration Time Curve Over the Dosing Interval

    Time frame: Up to 36 months.

  16. Terminal Half-Life (t1/2) of ONC206

    Time frame: Up to 36 months.

  17. Change from Baseline in European Organization for the Research and Treatment of Cancer Quality of Life-Core Questionnaire (EORTC-QLQ-C30)

    Time frame: Up to 36 months.

  18. Change from Baseline in Functional Assessment of Cancer Therapy - Bone Pain (FACT-BP)

    Time frame: Up to 36 months.

07

Study locations

9 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — In accordance with ICMJE requirements, Jazz Pharmaceuticals may provide qualified external researchers access to individual participant data (IPD) and clinical trial data that underlie the results of this trial upon request. Qualified researchers can submit a request on https://www.jazzpharma.com/science/clinical-trial-data-sharing/ as outlined. Jazz Pharmaceuticals reserves the right not to consider a request. For inquiries about Jazz's data sharing policy contact clinicaldatasharing@jazzpharma.com.

Data sharing details ↗ · www.jazzpharma.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2028, 35 months after the start.

Of 26 phase 2 interventional studies under Paraganglioma, half reached primary completion within 111 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 157. This study's planned 35 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2025
First posted
Dec 15, 2025
StartActual
Jan 2, 2026
Primary completionEst.
Dec 15, 2028
CompletionEst.
Dec 15, 2028
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed. U of Michigan is now Recruiting
Show site
  • Columbia University Irving Medical Center · New York, United States
Show 1 removed
  • Columbia University Medical Center · New York, United States
across 2 updates, Oct 2, 2026 – Oct 29, 2026
Show all 2 updates
  1. Oct 29, 2026
    1 site added, 1 site removed
    Show site
    • Columbia University Irving Medical Center · New York, United States
    Show 1 removed
    • Columbia University Medical Center · New York, United States
  2. Oct 2, 2026
    U of Michigan is now Recruiting
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07282587
Responsible party
Sponsor
First posted
Dec 15, 2025
Start date
Jan 2, 2026
Primary completion
Dec 15, 2028 (estimated)
Completion
Dec 15, 2028 (estimated)
Last update
Oct 29, 2026

Study contacts

Clinical Trial Disclosure & Transparency
Contact
ClinicalTrialDisclosure@jazzpharma.com
215-832-3750

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ONC206

Start the discussion